Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Leiman

Pain Medicine Houston, TX Medical Doctor

NPI 1184925703 CMS profile 281312

2001 Hermann Dr, Houston, TX 77004

Open in the dashboard

General payments

$130,831

161 records reported · program years 2019–2025

Research payments

$16,040

Paid to them · 38 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$150,012 paid to institutions, not to them · program years 2019–2023

Through program year 2025, David Leiman of Houston, TX is reported in the CMS Open Payments database as having received $130,831 across 161 general payments and $16,040 in research payments paid to them. Separately, studies naming them as principal investigator received $150,012 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $196 2
2024 General $7,304 5
2024 Research $2,375 10
2023 General $20,324 23
2023 Research $5,350 17
2022 General $21,531 23
2022 Research $2,075 9
2021 General $36,238 41
2020 General $4,355 9
2019 General $40,882 58
2019 Research $6,240 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Leiman
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to David Leiman were reported at $196. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year David Leiman Pain Medicine median Middle half National median
2019 $40,882 $498 $126–$1,682 $163
2020 $4,355 $284 $80–$910 $114
2021 $36,238 $399 $112–$1,219 $132
2022 $21,531 $455 $137–$1,484 $149
2023 $20,324 $484 $128–$1,495 $160
2024 $7,304 $498 $131–$1,540 $164
2025 $196 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acacia Pharma Inc $45,822 47 payments
  2. Eagle Pharmaceuticals, Inc. $27,247 24 payments
  3. Pacira Pharmaceuticals Incorporated $25,673 35 payments
  4. AcelRx Pharmaceuticals, Inc. $14,843 25 payments
  5. Heron Therapeutics, Inc. $14,628 16 payments
  6. Baudax Bio Inc. $1,105 1 payment
  7. Grifols Therapeutics LLC $904 4 payments
  8. Stryker Corporation $169 1 payment
  9. Vertex Pharmaceuticals Incorporated $156 2 payments
  10. Smith+Nephew, Inc. $133 1 payment
  11. Other $151 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $44,350 15 payments
  2. Honoraria $34,405 13 payments
  3. Consulting Fee $24,600 10 payments
  4. Travel and Lodging $22,259 67 payments
  5. Food and Beverage $5,217 56 payments
Products named General payments · program years 2019–2025
  1. Byfavo $73,040 70 payments
  2. EXPAREL Pain Management $25,292 32 payments
  3. DSUVIA $14,843 25 payments
  4. Zynrelef $10,197 11 payments
  5. Cinvanti $4,142 4 payments
  6. ANJESO $1,105 1 payment
  7. Alphanate $904 4 payments
  8. Exparel Pain Management $382 3 payments
  9. BARHEMSYS $301 2 payments
  10. Zilretta $217 1 payment
  11. Other $833 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $9,800 36 payments
  2. Eli Lilly and Company $6,240 2 payments

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record